|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2011-1-31
|
|
pubmed:abstractText |
Chemoembolization is one of several standards of care treatment for hepatocellular carcinoma (HCC). Radioembolization with Yttrium-90 microspheres is a novel, transarterial approach to radiation therapy. We performed a comparative effectiveness analysis of these therapies in patients with HCC.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1528-0012
|
|
pubmed:author |
pubmed-author:AbecassisMichaelM,
pubmed-author:AtassiBasselB,
pubmed-author:BakerTaliaT,
pubmed-author:BensonAl BAB3rd,
pubmed-author:ChenRichardR,
pubmed-author:ChrismanHoward BHB,
pubmed-author:GatesVanessa LVL,
pubmed-author:GuptaRamonaR,
pubmed-author:IbrahimSaad MSM,
pubmed-author:KulikLauraL,
pubmed-author:LewandowskiRobert JRJ,
pubmed-author:MILANGG,
pubmed-author:MemonKhairuddinK,
pubmed-author:MillerFrank HFH,
pubmed-author:MulcahyMary FMF,
pubmed-author:NemcekAlbert AAA,
pubmed-author:NewmanStevenS,
pubmed-author:NikolaidisPaulP,
pubmed-author:OmaryReed ARA,
pubmed-author:ResnickScott ASA,
pubmed-author:RiazAhsunA,
pubmed-author:RyuRobert KRK,
pubmed-author:SalemRiadR,
pubmed-author:SatoKent TKT,
pubmed-author:SenthilnathanSeanthanS,
pubmed-author:VogelzangRobert LRL,
pubmed-author:WangEdwardE,
pubmed-author:YaghmaiVahidV
|
|
pubmed:copyrightInfo |
Copyright © 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
140
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
497-507.e2
|
|
pubmed:dateRevised |
2011-7-6
|
|
pubmed:meshHeading |
pubmed-meshheading:21044630-Adult,
pubmed-meshheading:21044630-Aged,
pubmed-meshheading:21044630-Aged, 80 and over,
pubmed-meshheading:21044630-Carcinoma, Hepatocellular,
pubmed-meshheading:21044630-Chemoembolization, Therapeutic,
pubmed-meshheading:21044630-Clinical Trials, Phase II as Topic,
pubmed-meshheading:21044630-Disease Progression,
pubmed-meshheading:21044630-Embolization, Therapeutic,
pubmed-meshheading:21044630-Female,
pubmed-meshheading:21044630-Humans,
pubmed-meshheading:21044630-Liver Neoplasms,
pubmed-meshheading:21044630-Male,
pubmed-meshheading:21044630-Microspheres,
pubmed-meshheading:21044630-Middle Aged,
pubmed-meshheading:21044630-Neoplasm Staging,
pubmed-meshheading:21044630-Radiopharmaceuticals,
pubmed-meshheading:21044630-Randomized Controlled Trials as Topic,
pubmed-meshheading:21044630-Standard of Care,
pubmed-meshheading:21044630-Treatment Outcome,
pubmed-meshheading:21044630-Yttrium Radioisotopes
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma.
|
|
pubmed:affiliation |
Department of Radiology, Section of Interventional Radiology and Division of Interventional Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois 60611, USA. r-salem@northwestern.edu
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, N.I.H., Extramural
|
